Mild respiratory COVID can cause multi-lineage neural cell and myelin dysregulation

Anthony Fernández-Castañeda(Stanford University), Peiwen Lu(Yale University), Anna C. Geraghty(Stanford University), Eric Song(Yale University), Myoung‐Hwa Lee(National Institute of Neurological Disorders and Stroke), Jamie Wood(Icahn School of Medicine at Mount Sinai), Michael R. O’Dea, Selena Dutton(Stanford University), Kiarash Shamardani(Stanford University), Kamsi Nwangwu(Stanford University), Rebecca Mancusi(Stanford University), Belgin Yalçın(Stanford University), Kathryn R. Taylor(Stanford University), Lehi Acosta-Alvarez(Stanford University), Karen Malacon(Stanford University), Michael B. Keough(Stanford University), Lijun Ni(Stanford University), Pamelyn J. Woo(Stanford University), Daniel Contreras-Esquivel(Stanford University), Angus Toland(Stanford University), Jeff Gehlhausen(Yale University), Jon Klein(Yale University), Takehiro Takahashi(Yale University), Julio Silva(Yale University), Benjamin Israelow(Yale University), Carolina Lucas(Yale University), Tianyang Mao(Yale University), Mario A. Peña-Hernández(Yale University), Alexandra Tabachnikova(Yale University), Robert Homer(Yale University), Laura Tabacof(Icahn School of Medicine at Mount Sinai), Jenna Tosto‐Mancuso(Icahn School of Medicine at Mount Sinai), Erica Breyman(Icahn School of Medicine at Mount Sinai), Amy Kontorovich(Icahn School of Medicine at Mount Sinai), Dayna McCarthy(Icahn School of Medicine at Mount Sinai), Martha Quezado(National Cancer Institute), Hannes Vogel(Stanford University), Marco M. Hefti(University of Iowa), Daniel P. Perl(Uniformed Services University of the Health Sciences), Shane A. Liddelow(New York University), Rebecca D. Folkerth(Office of Chief Medical Examiner), David Putrino(Icahn School of Medicine at Mount Sinai), Avindra Nath(National Institute of Neurological Disorders and Stroke), Akiko Iwasaki(Howard Hughes Medical Institute), Michelle Monje(Howard Hughes Medical Institute)
Cited by 511Open Access
Full Text

Abstract

COVID survivors frequently experience lingering neurological symptoms that resemble cancer-therapy-related cognitive impairment, a syndrome for which white matter microglial reactivity and consequent neural dysregulation is central. Here, we explored the neurobiological effects of respiratory SARS-CoV-2 infection and found white-matter-selective microglial reactivity in mice and humans. Following mild respiratory COVID in mice, persistently impaired hippocampal neurogenesis, decreased oligodendrocytes, and myelin loss were evident together with elevated CSF cytokines/chemokines including CCL11. Systemic CCL11 administration specifically caused hippocampal microglial reactivity and impaired neurogenesis. Concordantly, humans with lasting cognitive symptoms post-COVID exhibit elevated CCL11 levels. Compared with SARS-CoV-2, mild respiratory influenza in mice caused similar patterns of white-matter-selective microglial reactivity, oligodendrocyte loss, impaired neurogenesis, and elevated CCL11 at early time points, but after influenza, only elevated CCL11 and hippocampal pathology persisted. These findings illustrate similar neuropathophysiology after cancer therapy and respiratory SARS-CoV-2 infection which may contribute to cognitive impairment following even mild COVID.


Related Papers

No related papers found

Powered by citation graph analysis